Neurocrine Biosciences, Inc. Live Stock Price Today, Share Analysis and Chart

Name: Neurocrine Biosciences, Inc.: Is Infosys Ltd. worth buying?
Item: Neurocrine Biosciences, Inc.
Rating: 2.281194375
Author: Trendlyne DVM scores

Mid-range Performer

about

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive ...

140.27 -1.73 (-1.22%)

66.53% Gain from 52W Low

903.1K

XNAS Volume

XNAS 29 Sep, 2025 5:30 PM (EDT)

Medium Financial Strength

44.4 / 100

Mid Valuation

34.7 / 100

Technically Neutral

58.9 / 100

Mid-range Performer These stocks average quality, financial and technical aspects make them being considered by the investor who are not looking for high risk stocks. View Similar Embed DVM

169

1Yr Price target upside is 20%

26 analysts

Neurocrine Biosciences Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Neurocrine Biosciences, Inc. Live Stock Price Today, Share Analysis and Chart

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive ...

66.53% Gain from 52W Low

SWOT Analysis

Neurocrine Biosciences Inc Live Price Chart